
    
      This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral
      interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of
      relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability,
      and anti-tumor activity of CPI-818 as a single drug. This trial is composed of dose
      escalation and dose expansion cohorts.
    
  